ASCO’s Leadership Development Program (LDP) prepares you to become a leader while giving you exclusive access to ASCO leaders and the broader oncology community, as well as a robust network of past ...

A new article in JCO Oncology Practice (JCO OP) looks at the root causes of cancer drug shortages in the United States (U.S.), the impact of these shortages on patients and providers, and makes ...

On June 20, 2025, the Centers for Medicare & Medicaid Services (CMS) released the 2025 Marketplace Integrity and Affordability final rule aimed at addressing improper enrollments in the ACA Health ...

Medicare Advantage Audits Are Expanding. What Do Oncology Practices Need to Know? Continuing its efforts to reduce fraud, waste, and abuse in Medicare, the Centers for Medicare & Medicaid Services ...

America’s Health Insurance Plans (AHIP)—a trade group representing the U.S. health insurance industry—announced a commitment from participating plans to improve prior authorization processes. The ...

American Society of Clinical Oncology (ASCO) and Egyptian Cancer Society (ECS) leaders signed a Memorandum of Understanding (MOU) on June 2, 2025, during ASCO’s 61st Annual Meeting. The MOU formally ...

While federal prior authorization reform legislation has yet to make it over the finish line and be enacted into law, state governments continue to pass legislation to mitigate the burdensome ...

Decentralized clinical trial elements can be safely adopted as permanent fixtures without substantial reductions in data quality or increased risk to research participants, according to a new study in ...

The American Society of Clinical Oncology (ASCO) has been notified of a recent safety notice for the drug Jubbonti (denosumab-bbdz) under the Food and Drug Administration’s Risk Evaluation and ...

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

CHICAGO — New study results show that a structured exercise program following surgery and adjuvant chemotherapy reduced the risk of recurrent or new cancer and increased survival for patients with ...